Summary
- Verastem Oncology updated investors on their RAMP programs, including RAMP 202 in KRAS G12V-Mutant NSCLC. The results of Part A failed to hit the conditions to progress.
- The market hammered VSTM following the update and is down roughly 70% at $0.40 a share with a market cap of around $84.5M.
- It appears as if the market might be apprehensive about avutometinib and that it might be a dud in NSCLC, as well as other KRAS cancers.
- I was disappointed with the update and decided to mothball my VSTM until fresh data can revitalize my thesis. My VSTM conviction rating is 1 out of 5 at this time.
- I will take a look at the company’s valuation and charts to see if I can find any signs of a turnaround or buying opportunities.
For further details see:
Verastem: Avutometinib Apprehension Puts My Position In Mothballs (Rating Downgrade)